NOVAVAX Business Summary

Novavax Inc. (NVAX) is a biotechnology company specializing in the development of recombinant protein-based vaccines, generating revenue through a mix of licensing fees, milestone payments, royalties, and product supply sales. Following a major strategic pivot in 2024 and 2025, the company transitioned from a manufacturing-heavy operation to a leaner, IP-focused model centered on its proprietary Matrix-M adjuvant technology and nanoparticle platform. This shift is anchored by a multi-billion dollar co-exclusive licensing agreement with Sanofi, which grants the latter commercial rights to Novavax’s COVID-19 vaccine, Nuvaxovid, and the right to utilize the Matrix-M adjuvant in its own vaccine pipeline. The company’s primary segments include its commercial COVID-19 portfolio, its Phase 3 COVID-19-Influenza Combination (CIC) vaccine candidate, and its adjuvant licensing business. Novavax competes directly with mRNA leaders Moderna and Pfizer/BioNTech, as well as AstraZeneca, positioning itself as the premier non-mRNA alternative for patients and healthcare systems seeking traditional protein-based vaccine technology. Founded in 1987 by Bror Morein and early key figures such as James F. Young and Mark Wilson, Novavax is currently led by President and CEO John C. Jacobs, who previously served as CEO of Harmony Biosciences and held leadership roles at Teva Pharmaceuticals and Pfizer. The executive leadership team includes EVP and CFO Jim Kelly, formerly CFO of Supernus and Vanda Pharmaceuticals; EVP and Head of R&D Ruxandra Draghia-Akli, MD, PhD, a global health expert who previously served as Global Head of Public Health R&D at Johnson & Johnson and VP at Merck; and EVP and COO Rick Crowley, who brings over 20 years of operations experience from TerSera and Savient Pharmaceuticals. The company is governed by a board of directors chaired by Margaret G. McGlynn and maintains significant institutional support from major shareholders including Sanofi, The Vanguard Group, BlackRock, and Shah Capital Management.